Exclusive Distribution Agreement

12 April 2010

Plethora Solutions Holdings plc

New Product Distribution Agreement

Plethora Solutions Holdings plc (AIM: PLE, 'Plethora'), the UK-based specialty pharmaceutical company, is pleased to announce that it has concluded an exclusive distribution agreement with Fidia Farmaceutici SpA to acquire UK marketing rights to Hyalofemme™, a product for the treatment of vaginal dryness. This is the third commercial agreement to be concluded through Plethora's marketing arm, The Urology Company, which was launched in the second half of 2009 to build a portfolio of approved products to market and distribute into the UK specialist urology market.

Hyalofemme™ is a proprietary gel formulation of hyaluronic acid, a naturally occurring polysaccharide with moisturising and lubricating properties, which has been designed for the relief of vaginal dryness. This common condition can arise from the hormonal changes that occur after childbirth, before and after the onset of menopause or as a result of medications used in the treatment of breast and ovarian cancers. Twice weekly application of Hyalofemme™ has been shown to result in a reduction in vaginal discomfort without adverse changes to the vaginal environment.

The Urology Company expects to launch Hyalofemme™ in the UK, where it has not been available previously, in the third quarter of 2010. The product will be marketed via retail pharmacies and also direct to consumers.

Antonio Germani, Fidia Farmaceutici's Chief Executive Officer, commented:

"This collaboration is a milestone for Fidia's international growth in the field of urology. We look forward to the launch of Hyalofemme™ in the UK and to increasing our activities in this clinical sector with our sodium hyaluronate based products."

Steven Powell, Chief Executive Officer, commented:

"Hyalofemme™ represents the fifth product to enter the product portfolio of The Urology Company and we are excited by the potential that this product has to meet specific clinical needs in a wide range of patient groups. We remain on-track to meet our objective of launching between six and nine products through The Urology Company this year and the continued growth of this subsidiary will complement the Group's development and licensing activities."

- ENDS -

Enquiries:

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Urology Company is Plethora's marketing and distribution business, established in August 2009, to target the UK urology market. The Urology Company markets a range of proprietary, branded and generic pharmaceutical products, together with selected medical devices and nutritional supplements. Products are marketed directly to specialist prescribing physicians, retail pharmacies and directly to consumers.

In addition, Plethora has a portfolio of products at varying stages of development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510 - 'Invicorp') and premature ejaculation (PSD502). Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L).

Further information is available at:

www.plethorasolutions.co.uk and www.theurologyco.com

About Fidia:

Fidia Farmaceutici S.p.A. is a privately held fully integrated Italian pharmaceutical company with R&D, manufacturing, marketing and sales capabilities. The company was established in 1946 and is headquartered in Abano Terme (Italy).

Fidia operates worldwide and develops and markets innovative healthcare products (medicinal products, medical devices and biomaterials), based on proprietary hyaluronic acid (HY) and its derivatives. Major business areas are in treatment and management of joint care/musculoskeletal disorders, including osteoarthritis and advanced wound Care/dermo-aesthetics. Fidia is a world leader in the production of hyaluronic acid both utilising proprietary and validated extraction and fermentation processes. Fidia's manufacturing operation is FDA-inspected and approved and complies with the strictest international guidelines including EU and US cGMP (21 CFR Part 211, 21 CFR Part 820, EU GMP), Quality Assurance ISO 9001:2000 and ISO 13485:2003 to ensure absolute safety and quality of its products.

Further information is available at:

www.fidiapharma.com